<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01159262</url>
  </required_header>
  <id_info>
    <org_study_id>DEX-09-08</org_study_id>
    <nct_id>NCT01159262</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age</brief_title>
  <official_title>A Phase II/III, Open-Label, Multicenter, Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Neonates Ages ≥28 Weeks to ≤44 Weeks Gestational Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospira, now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, efficacy and pharmacokinetics (PK) of
      dexmedetomidine (DEX) at 3 different dose levels in infants, ages ≥28 weeks to ≤44 weeks
      gestational age, administered as a loading dose followed by a continuous infusion for a
      minimum of 6 hours and up to 24 hours in the neonatal intensive care unit (NICU), cardiac
      intensive care unit (CICU), or pediatric intensive care unit (PICU).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Who Received Rescue Medication Midazolam for Sedation During Dexmedetomidine Infusion</measure>
    <time_frame>During study drug administration (6 to 24 hours)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Who Received Rescue Medication for Analgesia During Dexmedetomidine Infusion</measure>
    <time_frame>During Study drug administration (6 to 24 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Rescue Medication Midazolam Given for Sedation During Dexmedetomidine Infusion (Among Who Used)</measure>
    <time_frame>During Study drug administration (6 to 24 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Rescue Medication Fentanyl Given for Sedation During Dexmedetomidine Infusion (Among Who Used)</measure>
    <time_frame>During study drug administration (6 to 24 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Rescue Medication Morphine Given for Sedation During Dexmedetomidine Infusion (Among Who Used)</measure>
    <time_frame>During study drug administration (6 to 24 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-adjusted Total Amount (Per kg) of Rescue Medication Midazolam Given for Sedation During Dexmedetomidine Infusion (Among Who Used)</measure>
    <time_frame>During study drug administration (6 to 24 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-adjusted Total Amount (Per kg) of Rescue Medication Fentanyl Given for Analgesia During Dexmedetomidine Infusion (Among Who Used)</measure>
    <time_frame>During study drug administration (6 to 24 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-adjusted Total Amount (Per kg) of Rescue Medication Morphine Given for Analgesia During Dexmedetomidine Infusion (Among Who Used)</measure>
    <time_frame>During study drug administration (6 to 24 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Successful Extubation in DEX-exposed Subjects</measure>
    <time_frame>From start of DEX administration to extubation of each subject up to 7 days post-infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine 0.05 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 0.1 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 0.2 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Per package insert, N-PASS (Neonatal Pain, Agitation, and Sedation Scale) scores and investigator discretion</description>
    <arm_group_label>Dexmedetomidine 0.05 mcg/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 0.1 mcg/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 0.2 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl/Morphine</intervention_name>
    <description>Per package insert, N-PASS scores and investigator discretion.</description>
    <arm_group_label>Dexmedetomidine 0.05 mcg/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 0.1 mcg/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 0.2 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <arm_group_label>Dexmedetomidine 0.05 mcg/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 0.1 mcg/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 0.2 mcg/kg</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Initially intubated and mechanically ventilated pediatric subjects in an intensive
             care setting anticipated to require a minimum of 6 hours of continuous IV sedation.

          2. The ability to complete all PK sampling blood draws.

          3. Age: subjects must fit into 1 of the following age ranges at screening:

               -  Preterm neonates ≥28 weeks through &lt;36 weeks, gestational age; this would
                  constitute treatment Group I.

               -  Term neonates born at ≥36 weeks through ≤44 weeks gestational age; this would
                  constitute treatment Group II.

          4. Weight: subject's weight at the time of enrollment must be &gt;1000 g.

          5. Subject's parent(s) or legal guardian(s) has/have voluntarily signed and dated the
             informed consent document approved by the Institutional Review Board (IRB)/Independent
             Ethics Committee (IEC).

        Exclusion Criteria:

          1. Neonate subjects with neurological conditions that prohibit an evaluation of sedation
             such as:

               -  Diminished consciousness from increased intracranial pressure.

               -  The presence of catastrophic brain injury or other severe mental disorders that
                  would make responses to sedatives unpredictable and/or measurement of the N-PASS
                  unreliable.

               -  Subjects with immobility from neuromuscular disease or continuous infusion of
                  neuromuscular blocking (NMB) agents.

          2. Subjects with second degree or third degree heart block unless subject has a pacemaker
             or pacing wires are in situ.

          3. Heart rate &lt;120 bpm prior to the initiation of study drug.

          4. Exposure to any investigational drug within 30 days prior to study drug
             administration.

          5. Previous exposure to Dexmedetomidine (DEX) as part of an investigational study.

          6. Maternal history of poly-substance drug abuse, based upon the presence of 1) an
             abnormal urine drug screen for cocaine, opiates and/or benzodiazepines; or 2)
             Investigator's judgment.

          7. At the discretion of the Investigator, subjects in whom the risk of DEX treatment is
             expected to exceed its benefits.

          8. Subjects who have a known allergy or contraindication to fentanyl, morphine,
             Midazolam, DEX, or other α-2 agonists.

          9. Requirement for medications other than DEX, Midazolam, morphine, or fentanyl for
             sedation and pain control.

         10. Screening alanine aminotransferase (ALT) levels &gt;115 U/L.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Weeks</minimum_age>
    <maximum_age>44 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miller Children's Hospital</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco, Department of Pediatrics, Division of Neonatology</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0734</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Anesthesia, SUMC</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami - Miller School of Medicine, Department of Anesthesiology</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Health Sciences University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosair Charities Pediatric Clinical Research Unit, University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center, Department of Anesthesiology</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital Medical Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University School of Medicine</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zona 11 Guatemala</city>
        <zip>C.P. 01011</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Guatemala</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2010</study_first_posted>
  <results_first_submitted>January 24, 2014</results_first_submitted>
  <results_first_submitted_qc>December 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 12, 2014</results_first_posted>
  <disposition_first_submitted>September 12, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>September 12, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 14, 2012</disposition_first_posted>
  <last_update_submitted>July 23, 2015</last_update_submitted>
  <last_update_submitted_qc>July 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Initially intubated and mechanically ventilated neonates</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexmedetomidine 0.05 mcg/kg</title>
          <description>Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
Midazolam: Per package insert, N-PASS (Neonatal Pain, Agitation, and Sedation Scale) scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
        </group>
        <group group_id="P2">
          <title>Dexmedetomidine 0.1 mcg/kg</title>
          <description>Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
        </group>
        <group group_id="P3">
          <title>Dexmedetomidine 0.2 mcg/kg</title>
          <description>Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexmedetomidine 0.05 mcg/kg</title>
          <description>Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
        </group>
        <group group_id="B2">
          <title>Dexmedetomidine 0.1 mcg/kg</title>
          <description>Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
        </group>
        <group group_id="B3">
          <title>Dexmedetomidine 0.2 mcg/kg</title>
          <description>Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.637" spread="1.8290"/>
                    <measurement group_id="B2" value="1.098" spread="1.0849"/>
                    <measurement group_id="B3" value="2.225" spread="1.5779"/>
                    <measurement group_id="B4" value="1.558" spread="1.5382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>= 28 weeks to &lt; 36 weeks gestational age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 36 weeks to &lt;= 44 weeks gestational age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Who Received Rescue Medication Midazolam for Sedation During Dexmedetomidine Infusion</title>
        <time_frame>During study drug administration (6 to 24 hours)</time_frame>
        <population>Efficacy Evaluable Population: All subjects who received randomized Dexmedetomidine for at least 6 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine 0.05 mcg/kg</title>
            <description>Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.1 mcg/kg</title>
            <description>Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.2 mcg/kg</title>
            <description>Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Received Rescue Medication Midazolam for Sedation During Dexmedetomidine Infusion</title>
          <population>Efficacy Evaluable Population: All subjects who received randomized Dexmedetomidine for at least 6 hours.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="7.1"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Who Received Rescue Medication for Analgesia During Dexmedetomidine Infusion</title>
        <time_frame>During Study drug administration (6 to 24 hours)</time_frame>
        <population>Efficacy Evaluable Population: All subjects who received randomized Dexmedetomidine for at least 6 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine 0.05 mcg/kg</title>
            <description>Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.1 mcg/kg</title>
            <description>Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.2 mcg/kg</title>
            <description>Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Received Rescue Medication for Analgesia During Dexmedetomidine Infusion</title>
          <population>Efficacy Evaluable Population: All subjects who received randomized Dexmedetomidine for at least 6 hours.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7"/>
                    <measurement group_id="O2" value="35.7"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Amount of Rescue Medication Midazolam Given for Sedation During Dexmedetomidine Infusion (Among Who Used)</title>
        <time_frame>During Study drug administration (6 to 24 hours)</time_frame>
        <population>All subjects who received midazolam during Dexmedetomidine infusion</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine 0.05 mcg/kg</title>
            <description>Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.1 mcg/kg</title>
            <description>Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.2 mcg/kg</title>
            <description>Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Rescue Medication Midazolam Given for Sedation During Dexmedetomidine Infusion (Among Who Used)</title>
          <population>All subjects who received midazolam during Dexmedetomidine infusion</population>
          <units>Milligram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".360">Only 1 subject received rescue medication in the group. Standard deviation is not able to be calculated.</measurement>
                    <measurement group_id="O2" value=".500">Only 1 subject received rescue medication in the group. Standard deviation is not able to be calculated</measurement>
                    <measurement group_id="O3" value="1.125" spread="1.4637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Amount of Rescue Medication Fentanyl Given for Sedation During Dexmedetomidine Infusion (Among Who Used)</title>
        <time_frame>During study drug administration (6 to 24 hours)</time_frame>
        <population>All subjects who received fentanyl during Dexmedetomidine infusion</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine 0.05 mcg/kg</title>
            <description>Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.1 mcg/kg</title>
            <description>Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.2 mcg/kg</title>
            <description>Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Rescue Medication Fentanyl Given for Sedation During Dexmedetomidine Infusion (Among Who Used)</title>
          <population>All subjects who received fentanyl during Dexmedetomidine infusion</population>
          <units>Microgram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.808" spread="7.1305"/>
                    <measurement group_id="O2" value="5.667" spread="3.5119"/>
                    <measurement group_id="O3" value="9.522" spread="7.5131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Amount of Rescue Medication Morphine Given for Sedation During Dexmedetomidine Infusion (Among Who Used)</title>
        <time_frame>During study drug administration (6 to 24 hours)</time_frame>
        <population>All subjects who received morphine during Dexmedetomidine infusion</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine 0.05 mcg/kg</title>
            <description>Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.1 mcg/kg</title>
            <description>Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.2 mcg/kg</title>
            <description>Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Rescue Medication Morphine Given for Sedation During Dexmedetomidine Infusion (Among Who Used)</title>
          <population>All subjects who received morphine during Dexmedetomidine infusion</population>
          <units>milligram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.275" spread="0.0354"/>
                    <measurement group_id="O3" value="0.400" spread="0.1732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight-adjusted Total Amount (Per kg) of Rescue Medication Midazolam Given for Sedation During Dexmedetomidine Infusion (Among Who Used)</title>
        <time_frame>During study drug administration (6 to 24 hours)</time_frame>
        <population>All subjects who received midazolam during Dexmedetomidine infusion</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine 0.05 mcg/kg</title>
            <description>Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.1 mcg/kg</title>
            <description>Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.2 mcg/kg</title>
            <description>Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Weight-adjusted Total Amount (Per kg) of Rescue Medication Midazolam Given for Sedation During Dexmedetomidine Infusion (Among Who Used)</title>
          <population>All subjects who received midazolam during Dexmedetomidine infusion</population>
          <units>milligrams/Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.100">Only 1 subject received rescue medication in the group. Standard Deviation was not able to be calculated</measurement>
                    <measurement group_id="O2" value="0.152">Only 1 subject received rescue medication in the group. Standard Deviation was not able to be calculated</measurement>
                    <measurement group_id="O3" value="0.318" spread="0.4133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight-adjusted Total Amount (Per kg) of Rescue Medication Fentanyl Given for Analgesia During Dexmedetomidine Infusion (Among Who Used)</title>
        <time_frame>During study drug administration (6 to 24 hours)</time_frame>
        <population>All subjects who received fentanyl during Dexmedetomidine infusion</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine 0.05 mcg/kg</title>
            <description>Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.1 mcg/kg</title>
            <description>Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.2 mcg/kg</title>
            <description>Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Weight-adjusted Total Amount (Per kg) of Rescue Medication Fentanyl Given for Analgesia During Dexmedetomidine Infusion (Among Who Used)</title>
          <population>All subjects who received fentanyl during Dexmedetomidine infusion</population>
          <units>microgram/Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.137" spread="6.3696"/>
                    <measurement group_id="O2" value="1.863" spread="0.8761"/>
                    <measurement group_id="O3" value="2.725" spread="2.1383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight-adjusted Total Amount (Per kg) of Rescue Medication Morphine Given for Analgesia During Dexmedetomidine Infusion (Among Who Used)</title>
        <time_frame>During study drug administration (6 to 24 hours)</time_frame>
        <population>All subjects who received morphine during Dexmedetomidine infusion</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine 0.05 mcg/kg</title>
            <description>Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.1 mcg/kg</title>
            <description>Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.2 mcg/kg</title>
            <description>Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Weight-adjusted Total Amount (Per kg) of Rescue Medication Morphine Given for Analgesia During Dexmedetomidine Infusion (Among Who Used)</title>
          <population>All subjects who received morphine during Dexmedetomidine infusion</population>
          <units>milligram/Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.125" spread="0.0348"/>
                    <measurement group_id="O3" value="0.109" spread="0.0540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Successful Extubation in DEX-exposed Subjects</title>
        <time_frame>From start of DEX administration to extubation of each subject up to 7 days post-infusion</time_frame>
        <population>Efficacy Evaluable Population: All subjects who received randomized Dexmedetomidine for at least 6 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine 0.05 mcg/kg</title>
            <description>Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.1 mcg/kg</title>
            <description>Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.2 mcg/kg</title>
            <description>Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Successful Extubation in DEX-exposed Subjects</title>
          <population>Efficacy Evaluable Population: All subjects who received randomized Dexmedetomidine for at least 6 hours.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" lower_limit="4.467" upper_limit="100.67"/>
                    <measurement group_id="O2" value="49.3" lower_limit="33.167" upper_limit="79.583"/>
                    <measurement group_id="O3" value="23.7" lower_limit="4.667" upper_limit="67.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Start of study drug administration until 7 days following the start of study drug. Serious adverse events collected from signing of informed consent until 7 days following start of study drug administration or hospital discharge (whichever comes first).</time_frame>
      <desc>Patients were monitored for safety parameters from 6 to 24 hours in the ICU.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dexmedetomidine 0.05 mcg/kg</title>
          <description>Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
        </group>
        <group group_id="E2">
          <title>Dexmedetomidine 0.1 mcg/kg</title>
          <description>Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
        </group>
        <group group_id="E3">
          <title>Dexmedetomidine 0.2 mcg/kg</title>
          <description>Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
Midazolam: Per package insert, N-PASS scores and investigator discretion
Fentanyl: Per package insert, N-PASS scores and investigator discretion.
Dexmedetomidine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.8</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Patent ductus arteriosus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbiliruninaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Shunt stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin unconjugated increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anger</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Atelectasis neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypopnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Plueral effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Diastolic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marcelo Garcia de Rocha MD, Global Medical Director</name_or_title>
      <organization>Hospira</organization>
      <phone>224-212-4424</phone>
      <email>marcelo.rocha@hospira.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

